CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model
Open Access
- 4 October 2012
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 3 (10) , e396
Abstract
The chemokine receptor CXCR4 favors the interaction of acute myeloid leukemia (AML) cells with their niche but the extent to which it participates in pathogenesis is unclear. Here, we show that CXCR4 expression at the surface of leukemic cells allowed distinguishing CXCR4high from CXCR4neg/low AML patients. When high levels of CXCR4 are expressed at the surface of AML cells, blocking the receptor function with small molecule inhibitors could promote leukemic cell death and reduce NOD/Shi-scid/IL-2Rγnull (NOG) leukemia-initiating cells (LICs). Conversely, these drugs had no efficacy when AML cells do not express CXCR4 or when they do not respond to chemokine CXC motif ligand 12 (CXCL12). Functional analysis showed a greater mobilization of leukemic cells and LICs in response to drugs, suggesting that they target the interaction between leukemic cells and their supportive bone marrow microenvironment. In addition, increased apoptosis of leukemic cells in vitro and in vivo was observed. CXCR4 expression level on AML blast cells and their migratory response to CXCL12 are therefore predictive of the response to the inhibitors and could be used as biomarkers to select patients that could potentially benefit from the drugs.Keywords
This publication has 48 references indexed in Scilit:
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaBlood, 2012
- Identification of Hepatic Niche Harboring Human Acute Lymphoblastic Leukemic Cells via the SDF-1/CXCR4 AxisPLOS ONE, 2011
- The leukemic stem cell niche: current concepts and therapeutic opportunitiesBlood, 2009
- Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100Blood, 2009
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AMLBlood, 2009
- CXCR4 is required for the quiescence of primitive hematopoietic cellsJournal of Experimental Medicine, 2008
- Identification ofCXCR4as a New Nitric Oxide-Regulated Gene in Human CD34+ CellsStem Cells, 2006
- Intracellular Localization and Constitutive Endocytosis of CXCR4 in Human CD34+Hematopoietic Progenitor CellsStem Cells, 2004
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997